Rini Pauly

Rini Pauly

Auto-generated profile, based on publicly available information

Rini Pauly

Greenwood Genetic Center , Greenwood, SC 29646 USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2022 in Human Molecular Genetics
Verified
Journal Article
Closed access
PDF file
JCJessica A Cooley Coleman
Jessica A Cooley Coleman
JGJennifer M Gass
Jennifer M Gass
SSSujata Srikanth
Sujata Srikanth
RPRini Pauly
Rini Pauly
CZCatherine A Ziats
Catherine A Ziats
Luigi BoccutoLuigi Boccuto
Luigi Boccuto
Mosaic variants in the PIK3CA gene, encoding the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), produce constitutive PI3K activation which causes PIK3CA-related overgrowth spectrum (PROS) disorders. To date, fewer than 20 patients have been described with germline alterations in PIK3CA. In this study, we describe three unrelated individuals with overgrowth and germline PIK3CA variants. These variants were discovered through whole-exome sequencing and confirmed as germline by testing multiple tissue types, when available. Functional analysis using Patient 1’s fibroblast cell line and two previously reported patients’ cell lines showed increased phosphorylation of AKT during cellular starvation revealing constitutive activation of the PI3K/AKT/mTOR pathway. Alternatively, stimulation of the cells by fetal bovine serum produced a reduced response, indicating an activated status of the PI3K complex reducing the pathway response to further external stimulation. Additional studies utilizing Biolog Phenotype Microarray technology indicated reduced energy production when cells were exposed to growth factors stimulating the PI3K/AKT/mTOR pathway, confirming the trend observed in the AKT phosphorylation test after stimulation. Furthermore, treatment with inhibitors of the PI3K/AKT/mTOR pathway rescued the normal energy response in the patients’ cells. Collectively, these data demonstrate that disease-causing germline PIK3CA variants have a functional consequence, similar to mosaic variants in the PI3K/AKT/mTOR pathway.

7 May 2021 in Reviews on Recent Clinical Trials
Verified
Journal Article
Closed access
PDF file
RPRini Pauly
Rini Pauly
CZCatherine A. Ziats
Catherine A. Ziats
Ludovico AbenavoliLudovico Abenavoli
Ludovico Abenavoli
CSCharles E. Schwartz
Charles E. Schwartz
Luigi BoccutoLuigi Boccuto
Luigi Boccuto
Background: Autism spectrum disorder (ASD) is a complex neurodevelopmental condition that poses several challenges in terms of clinical diagnosis and investigation of molecular etiology. The lack of knowledge on the pathogenic mechanisms underlying ASD has hampered the clinical trials that so far have tried to target ASD behavioral symptoms. In order to improve our understanding of the molecular abnormalities associated with ASD, a deeper and more extensive genetic profiling of targeted individuals with ASD was needed. Methods: The recent availability of new and more powerful sequencing technologies (third-generation sequencing) has allowed to develop novel strategies for characterization of comprehensive genetic profiles of individuals with ASD. In particular, this review will describe integrated approaches based on the combination of various omics technologies that will lead to a better stratification of targeted cohorts for the design of clinical trials in ASD. Results: In order to analyze the big data collected by assays such as whole genome, epigenome, transcriptome, and proteome, it is critical to develop an efficient computational infrastructure. Machine learning models are instrumental to identify non-linear relationships between the omics technologies and therefore establish a functional informative network among the different data sources. Conclusion: The potential advantage provided by these new integrated omics-based strategies is to better characterize the genetic background of ASD cohorts, identify novel molecular targets for drug development, and ultimately offer a more personalized approach in the design of clinical trials for ASD.

1 November 2019 in Advances in Molecular Pathology
Verified
Journal Article
Closed access
RPRini Pauly
Rini Pauly
CSCharles E. Schwartz
Charles E. Schwartz